JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

JNJ

239.99

+0.58%↑

UNH

273.88

-1.05%↓

TMO

541.25

-1.25%↓

ABT

112.24

+1.31%↑

ISRG

497.33

+0.87%↑

Search

Codexis Inc

Avatud

SektorTervishoid

1.26 -2.33

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.26

Max

1.32

Põhinäitajad

By Trading Economics

Sissetulek

-6.3M

-20M

Müük

-6.7M

8.6M

Kasumimarginaal

-228.055

Töötajad

188

EBITDA

-3.4M

-16M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-74M

130M

Eelmine avamishind

3.59

Eelmine sulgemishind

1.26

Uudiste sentiment

By Acuity

60%

40%

289 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Codexis Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. nov 2025, 21:37 UTC

Tulu

Codexis to Cut About 24% of Workforce

Võrdlus sarnastega

Hinnamuutus

Codexis Inc Prognoos

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.25 / 2.53Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

289 / 352 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat